YWYi-Chih Wang

Yi-Chih Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yi-Chih Wang has a total of 155 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Combined Prognostic Value of Cardiac Magnetic Resonance–Derived Myocardial Extracellular Volume and the Fibrosis‐4 Index in Patients With Heart Failure With Preserved Ejection Fraction

    by Chen‐Yu Huang, Yen‐Liang Lin, Ting‐Tse Lin, Cho‐Kai Wu, Yi‐Chih Wang, Lian‐Yu Lin

    Background: Heart failure with preserved ejection fraction is increasingly recognized as a multisystem metabolic–inflammatory syndrome. We investigated the comparative and complementary prognostic value of cardiac magnetic resonance–derived extracellular volume fraction (ECV) and the Fibrosis‐4 index for predicting adverse cardiovascular outcomes in patients with heart failure with preserved ejection fraction. Methods: Between 2017 and 2019, 250 patients with heart failure with preserved ejection fraction underwent assessment of myocardial ECV by cardiac magnetic resonance and hepatic fibrosis using the Fibrosis‐4 index. The primary outcome was a composite of cardiovascular death or heart failure hospitalization. Multivariable Cox regression and discrimination analyses were performed to evaluate prognostic performance. Results: During a median follow‐up of 1190 days, 75 patients (30.0%) experienced the primary outcome. Both ECV (hazard ratio [HR], 1.13 [95% CI, 1.08–1.17]; P P =0.015) independently predicted the primary outcome. Patients with concomitantly elevated ECV and Fibrosis‐4 index had a markedly increased risk of adverse events compared with those with low values of both markers. ECV‐based models demonstrated superior discrimination compared with Fibrosis‐4–based models (concordance index, 0.732 versus 0.663; P =0.011). Addition of ECV to the Fibrosis‐4 model significantly improved discrimination, whereas addition of the Fibrosis‐4 index to the ECV model improved reclassification (continuous net reclassification improvement and integrated discrimination improvement) but not discrimination. Conclusions: Both myocardial ECV and the Fibrosis‐4 index independently predict adverse cardiovascular outcomes in heart failure with preserved ejection fraction. Although ECV provides greater prognostic discrimination, combined assessment of ECV and the Fibrosis‐4 index identifies a subgroup at particularly high risk and may provide complementary information for risk stratification.

  • Open Access

    Feasibility and long-term outcomes of recanalization for De novo small vessel chronic total occlusions

    by Jen-Fang Cheng, Cheng-Ting Tsai, Chien-Lin Lee, Jiun-Yang Chiang, Shih-Chi Liu, Chi-Jen Chang, Chia-Pin Lin, Chi-Hung Huang, Jun-Ting Liou, Chia-Ti Tsai, et al.

  • Open Access

    Application of the J-CTO Score to Recanalization for In-Stent Chronic Total Occlusions

    by Chieh-Yu Chen, Chi-Hung Huang, Jen-Fang Cheng, Chien-Lin Lee, Jiun-Yang Chiang, Shih-Chi Liu, Chi-Jen Chang, Chia-Pin Lin, Cheng-Ting Tsai, Jun-Ting Liou, et al.

  • Open Access

    Impact of aging on long-term cardiac outcomes of true-lumen recanalized chronic total occlusions in patients with overweight/obesity

    by Jen-Fang Cheng, Chien-Lin Lee, Jiunn-Yang Chiang, Shih-Chi Liu, Chi-Hung Huang, Jun-Ting Liou, Chi-Jen Chang, Cheng-Ting Tsai, Chia-Ti Tsai, Yi-Chih Wang, et al.

    Background Obesity paradox addressing all-cause mortality has been described in several chronic total occlusion (CTO) studies. However, the impact of aging on long-term cardiac events in patients with overweight and obesity with CTO recanalization were less studied. Methods A total of 458 patients (64.4 ± 11.3 years, 403 male) with CTO interventions were enrolled. The overweight/obesity group included 311 patients with body mass index (BMI) ≧24 kg/m2 and the non-obesity group included 147. With a median follow-up of 40.0 (17.9–61.4) months, 422 patients with successful true-lumen recanalization were further assessed for target lesion failure [TLF: cardiac death, target vessel myocardial infarction (TVMI), target lesion revascularization (TLR)]. Results At follow-up, the rates of cardiac death, TVMI, TLR, TLF, and stent thrombosis were 1.9%, 1.9%, 9.2%, 10.7%, and 0.5%, respectively. The TVMI-free survival was borderline better (p = 0.067 by log-rank test) in overweight/obesity than non-obesity group. Among patients p = 0.013 compared to non-obesity group by log-rank test). In multivariate Cox regression model, the non-obesity patients younger than 65 years were at a higher risk of TVMI, not only among those <65 years of age (hazard ratio = 11.0, 95% CI = 1.1–106.0) but also among the whole patients (hazard ratio=6.9, 95% CI = 1.4–35.1) with successful CTO recanalization. Conclusions For those with true-lumen recanalized CTO, the higher risk of TVMI after successful recanalization was rather evident in patients <65 years of age and without overweight/obesity, suggesting that aging might attenuate prognostic significance of “obesity paradox” for CTO interventions.


  • Open Access

    Role of calcification in J-CTO score: a viewpoint of intraplaque guidewire tracking techniques

    by Shih-Chi Liu, Chien-Lin Lee, Jen-Fang Cheng, Jiunn-Yang Chiang, Cheng-Ting Tsai, Chi-Jen Chang, Chia-Pin Lin, Chi-Hung Huang, Jun-Ting Liou, Chia-Ti Tsai, et al.

    As the burden and distribution of calcification within chronic total occlusion (CTO) lesions can be diverse, its effect on CTO recanalization using multiple devices and techniques is debatable. This study investigated the role of calcification in wiring-based intraplaque tracking techniques for CTO recanalization. A modified J-CTO score without counting calcification was used to analyze the procedures of 458 consecutive patients who underwent CTO interventions. Failed guidewire crossing and intraplaque tracking were considered procedural failures. Recanalization time details were analyzed for successful procedures. In patients with calcified CTO, the rate of procedural success only significantly declined to be lower than that of noncalcified CTO when the modified J-CTO score was ≥3 (77% vs. 94%, p = 0.008). In 422 patients with successful procedures, the presence of calcification was irrelevant to guidewire crossing time, but was accompanied with longer time from guidewire cross to final angiogram when the modified J-CTO score was 1-2 (53 ± 35 vs. 35 ± 17 [noncalcified] min, p < 0.001). Multivariate analyses showed that calcification was independently associated with procedural failure (odds ratio [OR] = 5.1, 95% confidence interval [CI] = 1.4-18.3) in lesions with modified J-CTO ≥3, and prolonged angioplasty/stenting procedures >60 min (OR = 4.8, 95% CI = 2.2-10.2) in successfully recanalized lesions with modified J-CTO score 1-2. Using intraplaque guidewire tracking, calcification was unfavorable for very difficult CTO lesions, and caused prolongation of angioplasty time for lesions with moderate complexity. This suggested that the role of calcification in the J-CTO score could be altered when different recanalization techniques were applied for CTO interventions.


  • Open Access

    Application of the J-CTO Score to Intraplaque Guidewire Tracking-Based Recanalization for In-Stent Chronic Total Occlusions

    by Chieh-Yu Chen, Chi-Hung Huang, Jen-Fang Cheng, Chien-Lin Lee, Jiunn-Yang Chiang, Shih-Chi Liu, Chi-Jen Chang, Chia-Pin Lin, Cheng-Ting Tsai, Jun-Ting Liou, et al.

    Background: The application of the J-CTO score for in-stent chronic total occlusion (CTO) recanalization remains unclear. We aimed to compare the role of J-CTO score in in-stent and de novo CTO interventions using intraplaque guidewire tracking techniques. Methods: The application of the J-CTO score to assess procedural feasibility and guidewire crossing time for in-stent (N=74, 14.6%) and de novo CTO (N=434, 85.4%) interventions was evaluated in consecutive 508 patients (64.1±11.6 years, 446 men). Failed intraplaque tracking (N=3) or guidewires crossing (N=35) was considered procedural failures (38/508=7.5%). Results: The procedural success rate for de novo CTOs significantly declined when the J-CTO score was >2 (85 vs. ≤2: 97%, p2: 96 vs. ≤2: 100%, p=0.400). Among 470 patients with successful recanalization, the guidewire crossing time ≥30 minutes was required less for in-stent than for de novo CTOs (OR=0.40, 95% CI=0.18-0.86) with J-CTO score ≥2 in multivariate analysis. For those with successful antegrade-only wiring, the guidewire crossing time shown by Kaplan–Meier curves was significantly related to the J-CTO score for either in-stent (N=72) or de novo (N=370) CTOs (both p<0.001 by log-rank test). However, only blunt stump (15.0±5.6 min) and occlusion ≥20mm (16.2±5.6 min) were independent time-determining factors of guidewire crossing (both p<0.01) for in-stent CTOs. Conclusion: With the intraplaque tracking strategy, the effects of the J-CTO score on procedural feasibility and guidewire crossing time differ for in-stent and de novo CTOs. Therefore, the J-CTO score should be cautiously interpreted during in-stent CTO interventions.

  • Open Access

    Stroke risk assessment in different atrial fibrillation subtypes: CHA2DS2-VASc score and beyond

    by C C Cheng, P S Huang, J J Chen, S N Chang, F C Chiu, C K Wu, J J Hwang, Y C Wang, C T Tsai

    Background: Patients with atrial fibrillation (AF) have been known to have an inhomogeneous risk of stroke, with several well-documented risk factors including hypertension, history of stroke, and diabetes mellitus that have been incorporated into the CHA2DS2–VASc score to stratify risk levels. Accumulating evidence has suggested that AF subtype, namely persistent AF and paroxysmal AF, also have an impact on stroke development. Purpose: This study focused on the impact of AF subtype on stroke risk in a large, long-term follow-up cohort as to provide insight of the impact on ischemic stroke risks. Such findings may play a role in future ischemic stroke risk stratification in selected patients. Methods: A total of 7346 AF patients were followed up for 10 years from January 2010 to December 2020 (mean follow-up time 2.74 years). Among these patients, 2460 (33.5%) had persistent or permanent AF (PerAF) and 4886 (66.5%) had paroxysmal AF (PAF). The study evaluated the risk of ischemic stroke between the two groups using Cox models adjusting for all components of the CHA2DS2–VASc score. Analyses were further stratified into the usage of oral anticoagulation (OAC) or no OAC. Results: Comparing AF patients based on subtype, it was found that PerAF patients were older, had a higher prevalence of previous stroke, congestive heart failure, PAD, DM, and were more often prescribed anticoagulants. Univariate analysis found patients with PerAF at a higher risk for ischemic stroke (HR 1.262, p<0.001). The results remained significant after multivariate analysis with factors of the CHA2DS2–VASc score (HR 1.234, p<0.001). After stratifying patients according to anticoagulation prescription, PerAF and PAF patients were found to have similar rates of developing ischemic stroke in patients under DOAC. Conclusions: Patients with PerAF have a higher risk of stroke during follow-up independent of components of the CHA2DS2VASc score. In patients with OAC use, there was no difference in stroke risk between AF subtypes.Stroke Risk in OAC-naive patientsStroke Risk in OAC-experienced patients

  • Open Access

    Pattern of Endothelialization in Left Atrial Appendage Occluder by Optic Coherence Tomography: A Pilot Study

    by Jien‐Jiun Chen, Fu‐Chun Chiu, Sheng‐Nan Chang, Hsiao‐Liang Cheng, Pang‐Shuo Huang, Cho‐Kai Wu, Yi‐Chih Wang, Juey‐Jen Hwang, Chia‐Ti Tsai

    Background: Implantation of the left atrial appendage occluder (LAAO) has been proven to prevent stroke effectively in patients with atrial fibrillation who cannot tolerate anticoagulants. Incomplete endothelization of LAAO may cause device‐related thrombus, and currently no good image modality exists to clearly see LAAO endothelialization. We aimed to use coronary optic coherence tomography (OCT) to visualize LAAO endothelialization. Methods and Results: We enrolled 14 patients (72.8±9.4 years old) undergoing pulmonary vein isolation with a preexisting LAAO implanted more than 1 year ago (5 Watchman and 9 Amulet). After pulmonary vein isolation, we did OCT via steerable sheath and coronary guiding catheter to adjust OCT probe location and injected contrast medium to visualize the LAAO surface. In vitro testing was also performed to see the bare occluder. In vitro OCT showed the surface of the bare device as an interrupted granule pattern, which included the Watchman surface polytetrafluoroethylene membrane string, Amulet disc metal strut, and inner polytetrafluoroethylene membrane string. In the implanted Watchman, OCT showed endothelialization as a smooth surface layer with noninterrupted coarser granules. In the implanted Amulet, OCT showed endothelialization as thin (early) or thick (late) endothelialization layer covering struts with OCT shadows. Among patients with Watchman, 2 showed no, 2 early, and 1 complete endothelialization. Among patients with Amulet, 2 showed no, 3 early, and 4 late endothelialization. Conclusions: We demonstrated the feasibility of OCT to visualize LAAO endothelization with high resolution. Further studies are needed to determine antithrombotic regimens if incomplete endothelization is detected. A new OCT catheter may be designed specifically for LAAO.